Table 2.
Comparison between baseline, 6 month and 12 month time-point measurements after anti-VEGF treatment
| Baseline (n = 19) | 6 month (n = 17) |
12 month (n = 16) |
Overall comparison p-value | Baseline-6 month p-value | 6 month–12 month p-value | |
|---|---|---|---|---|---|---|
|
FAZ area mm2 (SD) |
0.307 (± 0.133) |
0.3 (± 0.1) |
0.313 (± 0.1) |
0.6† | 0.5* | 0.10* |
|
Perimeter mm2 (SD) |
2.415 (± 0.692) |
2.4 (± 0.5) |
2.394 (± 0.4) |
0.7† | 0.9* | 0.3* |
|
Choroid thickness µm (SD) |
335.9 (± 39.1) |
347.2 (3 ± 8.1) |
336.8 (± 44.6) |
0.7† | 0.4* | 0.3∆ |
|
Choriocapillaris whole image density % (SD) |
62.6 (± 6.1) |
63.4 (± 6.4) |
63.9 (± 6.9) |
0.9† | 0.7* | 0.5* |
|
Choriocapillaris foveal area density % (SD) |
61.2 (± 7.4) |
60.6 (± 8.8) |
59.1 (± 7.9) |
0.85† | 0.8∆ | 0.3* |
|
Choriocapillaris parafoveal area density % (SD) |
61.9 (± 6.6) |
63.2 (± 6.6) |
64.1 (± 7.3) |
0.9† | 0.5* | 0.7* |
|
Retinal whole image density % (SD) |
46.9 (± 5.1) |
45.3 (± 5.2) |
45.7 (± 5.0) |
0.5† | 0.4* | 0.5* |
|
Retinal foveal area density % (SD) |
27.6 (± 5.9) |
25.2 (± 6.9) |
25.0 (± 6.8) |
0.2† | 0.3* | 0.07* |
|
Retinal parafoveal area density % (SD) |
49.0 (± 5.6) |
47.5 (± 5.7) |
48 (± 4.9) |
0.6† | 0.1∆ | 0.6* |
|
CST µm (SD) |
397.1 (± 93.2) |
300.4 (± 67.8) |
294.2 (± 71.5) |
0.005 † | 0.001* | 0.7* |
|
Visual acuity ETDRS (SD) |
69.6 (± 7.9) |
72.2 (± 7.9) |
73.9 (± 7.2) |
0.3† | 0.2* | 0.3* |
Italic values indicate the statistical significance
SD standard deviation, FAZ foveal avascular zone, CST central subfield thickness, ETDRS early treatment diabetic retinopathy study
* T-test, ∆Mann–Whitney, †One-way ANOVA